Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EPS (Weighted Average and Diluted) (2020 - 2025)

Intellia Therapeutics (NTLA) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.82 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 34.92% to -$0.82 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.82 through Dec 2025, up 27.1% year-over-year, with the annual reading at -$3.81 for FY2025, 27.43% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.82 at Intellia Therapeutics, up from -$0.92 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.82 in Q4 2025, with the low at -$1.96 in Q1 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.25, with a median of -$1.26 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 53.61% in 2022, then surged 40.31% in 2023.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$1.1 in 2021, then decreased by 25.45% to -$1.38 in 2022, then decreased by 5.8% to -$1.46 in 2023, then rose by 13.7% to -$1.26 in 2024, then skyrocketed by 34.92% to -$0.82 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.82, -$0.92, and -$0.98 for Q4 2025, Q3 2025, and Q2 2025 respectively.